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Abstracts / Osteoarthritis and Cartilage 28 (2020) S86eS527S120EVs from the two autologous blood derived products PRP and the cell
free alternative hyperacute (hypACT) serum in an inflammation model
was investigated.
Methods: PRP and hypACT serum were generated by double or single
centrifugation of whole blood. EVs were isolated from PRP and hypACT
serum by differential ultracentrifugation and concentration and size of
the EVs were determined by Nanoparticle Tracking Analysis (NTA). To
generate an inflammation model, human primary monocytes were
differentiated and activated into inflammatory (M1) macrophages and
patient-derived OA chondrocytes were co-cultivated together with
these M1 macrophages to mimic an inflammatory environment as
present in OA. Culture medium was supplemented with EVs isolated
from either PRP or hypACT serum and as control medium was supple-
mented with either FCS or EV-depleted FCS. Secretion of the inflam-
matory cytokines IL6, TNFa and IL1b were meassured by ELISA. mRNA
expression of the cartilage specific genes SOX9, Collagen 2 and Aggre-
can as well as of the matrix degrading enzymes MMP3 and MMP13 was
assessed by RT-PCR. Protein expression of NFkb and COX2, proteins
known to be involved in cartilage degradation during OA, was deter-
mined by Western Blot.
Results: In the presence of EVsisolated from blood derived products,
secretion of inflammatory cytokines was strongly reduced within the
inflammationmodel. In addition, expression of chondrogenic genes was
upregulated when EVs were added to the medium. Furthermore, EVs
could reduce the expression of the transcription factor NFkb and hence
also of its target gene COX2.
Conclusions: Within an inflammation model, EVs from blood derived
products harbor the potential to downregulate the secretion of
inflammatory cytokines as well as the expression of proteins promoting
extracellular matrix degradation. On the other hand, EVs can revert the
osteoarthritic phenotype of patient-derived OA chondrocytes to a more
hyaline one. Taken together, EVs from blood derived products can
overcome the limits of using the whole blood derived product for car-
tilage regeneration while offering comparable biological effects. They
can be seen as a minimally invasive injective biological approach for the
treatment of OA.
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BOSWELLIA SERRATA EXTRACT AND CURCUMIN INCREASE GDF15
PRODUCTION BY HUMAN PRIMARY OSTEOARTHRITIS CHOND-
ROCYTES: A NEW MECHANISM OF ACTION
C. Sanchez 1, J. Zappia 1, Y. Dierckxsens 2, J.-P. Delcour 3, Y. Henrotin 1.
1Univ. of Liege, liege, Belgium; 2 Tilman, Baillonville, Belgium;
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Purpose: Boswellia serrata extract (BSE) and curcumin are used to relief
symptoms in osteoarthritis (OA). This study aims to better understand
the mode of action of these compounds on OA chondrocytes in vitro.
Methods: Therapeutic plasmatic concentrations of the different com-
ponents of BSE correspond to an in vitro range from 25 to 100 mg/ml of
total BSE (100 mg/ml of BSE corresponds to 9.2 mM of 11-keto-b-bos-
wellic acid (KBA), 5.2 mMof acetylKBA, 22 mMde aBA, 34 mMde bBA, 4.4
mM de acetylaBA and 13.2 acetyl bBA), and between 2 to 10 mM for
bioavaibility-increased curcumin. BSE (5-100 mg/ml) and curcumin
(0.04 to 4 mg/ml corresponding to 0.1 to 10 mM) were tested separately
on primary chondrocytes from 3 OA patients. Lactate Deshydrogenase
LDH, nitrite (NO2), interleukin (IL)-6 and Growth Differentiation Factor
(GDF)15 were quantified in 72h-treated supernatant using enzyme
activity, Griess reaction and ELISAs, respectively.
Results: No mortality was observed at the tested concentrations. BSE
and curcumin both decreased concentration-dependently NO2 and IL-6
production, and increased GDF15 production. For NO2 production, the
decrease was observed from 0.2 mg/ml of curcumin and 10 mg/ml of BSE.
For IL-6 production, the decrease was observed from 1 mg/ml for cur-
cumin and 10 mg/ml for BSE. For GDF-15, the increase was observed
from 2 mg/ml for curcumin and 50 mg/ml for BSE. Maximal effect was
observed at 4 mg/ml for curcumin: -67% NO2 (p<0.0001), -71% IL-6
(p¼0.0001) andþ80% GDF15 (p<0.0001) and at 100 mg/ml for BSE: -40%
NO2 (p¼0.0003), -70% IL-6 (p¼0.0003) andþ73% for GDF15 (p¼0.0017).
Conclusions: At therapeutic plasmatic concentrations, BSE and curcu-
min decreased the production of NO2 and IL-6, two inflammatory
mediators. Furthermore, BSE and curcumin enhanced GDF-15 pro-
duction, an anti-inflammatory growth factor. GDF15 was first identified
as Macrophage inhibitory cytokine-1 or NSAID-activated gene-1 (by a
prostanoid-independent manner), and is known as a regulator ofinflammatory, cell repair and apoptosis pathways. GDF-15 has pro-
apoptotic and anti-tumorigenic activity in vitro and in vivo. It could
represent a new pathway explaining the beneficial effects of BSE and
the curcumin on synovium inflammation and cartilage degradation.
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EVALUATING CYTOKINES AS BIOMARKERS FOR TRAPEZIO-
METACARPAL OSTEOARTHRITIS
A. Ratneswaran, J. Rockel, K. Shestopaloff, D. Antflek, M. Kapoor,
H. Baltzer. Arthritis Res. Program, Univ. Hlth.Network, Toronto, ON,
Canada
Purpose: Osteoarthritis at the base of the thumb (Trapeziometacarpal
Osteoarthritis (TMOA) is a prevalent, degenerative condition leading to
pain, deformity and disability. Patients with TMOA have difficulty
grasping, writing, and performing other activities necessary for working
and daily living. End-stage TMOA is treated with arthroplasty, and little
information exists pertaining to long term outcomes of intervention.
Non-operative management demonstrates only short-term sympto-
matic alleviation, and no approved disease modifying drugs exist to
treat or delay this condition. A key issue in this patient population is
that radiographic disease severity is typically discordant with patient
reported pain, illustrating the need for objective markers to detect the
disease earlier, as well as predict whowill progressmore quickly to end-
stage disease, andwhowould benefit most from surgical treatment. Our
study seeks to characterize the biochemical profile of TMOA patients in
order to establish new diagnostic and prognostic tools, and elucidate
molecular mechanisms driving TMOA progression.
Methods: To determine the biochemical profile of TMOA patients we
have compared plasma and synovial fluid of patients with symptomatic
TMOA undergoing surgical (n¼37) or non-surgical management
(n¼35), and followed them up to 1-year post-surgery using targeted
inflammatory cytokine panels (Bio-Plex Pro TM Human Cytokine 27-plex
assay). We have also collected radiographic (Eaton-Littler), anthro-
pometric and longitudinal pain (VAS, TASD, quickDASH) and functional
(key pinch, grip strength) data to evaluate relationships between
structure, pain, and systemic and local cytokine expression.
Results: Our data demonstrate no significant differences in age, sex,
BMI, or radiographic score between surgical and non-surgically man-
aged patients. Patients undergoing surgery have significantly higher
pain as determined by quick DASH (54.5±18.3 vs 35.2±20.2, p<0.0001),
Visual Analog Scale (70.8±16 vs 51.1±27.2, p<0.001), and Tra-
peziometacarpal Arthrosis Symptoms and Disability Questionnaire
(60.4±17.6 vs 43.1±19.6, p<0.001). Systemically, these patients can be
distinguished by differing levels of Interleukin-7, Granulocyte Macro-
phage Colony Stimulating Factor, Interleukin 1 A Receptor Antagonist,
Monocyte Chemoattractant Protein 1, and Interferon Gamma, (p<0.0.5)
at baseline. Additionally, 1-year follow-up of surgical patients indicate
that four cytokines: Eotaxin, Interleukin 7, Interleukin 4, and Gran-
ulocyte Colony Stimulating Factor significantly change 6-months post-
surgery and maintain this change 1 year post surgery (p<0.05). Inter-
estingly, our data indicate that regardless of surgical status, a subset of
patients with an “inflammatory” phenotype exists.
Conclusions: Overall, our study has demonstrated that circulating
cytokines are capable of distinguishing TMOA disease severity, and has
identified promising targets that have potential to be used as prognostic
markers after validation in other cohorts. We have also identified a
cluster of patients who self-segregate based on a group of inflammatory
cytokines. Further evaluation of this patient subset may help develop an
approach to personalized medicine among this population.
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DISTINCT GALECTIN PROFILE IN INFLAMMATION-MEDIATED CARTI-
LAGE DAMAGE
S. Hayer 1,2, B. Niederreiter 1, R. Windhager 3, D. Aletaha 1, H.-J. Gabius 4,
S. Toegel 3,2. 1Dept. of Internal Med. III, Div. of Rheumatology, Med. Univ.
of Vienna, Vienna, Austria; 2 Ludwig Boltzmann Inst. for Arthritis and
Rehabilitation, Vienna, Austria; 3Dept. of Orthopedics and Trauma
Surgery, Karl Chiari Lab for Orthopaedic Biology, Med. Univ. of Vienna,
Vienna, Austria; 4 Inst. of Physiological Chemistry, faculty of Vet. Med.,
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Purpose: Galectins (Gal) are a family of carbohydrate binding proteins
that serve as regulators of fundamental numerous biological processes
